Last reviewed · How we verify
IIA2：3E9 PFU of oncolytic virus, sequentially combination
IIA2：3E9 PFU of oncolytic virus, sequentially combination is a Biologic drug developed by Peking University. It is currently in Phase 1 development.
At a glance
| Generic name | IIA2：3E9 PFU of oncolytic virus, sequentially combination |
|---|---|
| Sponsor | Peking University |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IIA2：3E9 PFU of oncolytic virus, sequentially combination CI brief — competitive landscape report
- IIA2：3E9 PFU of oncolytic virus, sequentially combination updates RSS · CI watch RSS
- Peking University portfolio CI
Frequently asked questions about IIA2：3E9 PFU of oncolytic virus, sequentially combination
What is IIA2：3E9 PFU of oncolytic virus, sequentially combination?
IIA2：3E9 PFU of oncolytic virus, sequentially combination is a Biologic drug developed by Peking University.
Who makes IIA2：3E9 PFU of oncolytic virus, sequentially combination?
IIA2：3E9 PFU of oncolytic virus, sequentially combination is developed by Peking University (see full Peking University pipeline at /company/peking-university).
What development phase is IIA2：3E9 PFU of oncolytic virus, sequentially combination in?
IIA2：3E9 PFU of oncolytic virus, sequentially combination is in Phase 1.